Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
Drugs Context
.
2019 Mar 4:8:212569.
doi: 10.7573/dic.212569.
eCollection 2019.
Authors
Vincenzo Accurso
1
,
Marco Santoro
1
,
Salvatrice Mancuso
1
,
Marisante Napolitano
1
,
Florinda Di Piazza
2
,
Antonio Russo
2
,
Sergio Mario Siragusa
1
Affiliations
1
Divisione di Ematologia A.O.U.P. Palermo, Palermo, Italy.
2
Laboratorio di Biologia Molecolare oncologia A.U.O.P Palermo, Palermo, Italy.
PMID:
30853998
PMCID:
PMC6400146
DOI:
10.7573/dic.212569
No abstract available
Keywords:
IPSS; primary myelofibrosis; ruxolitinib.
Publication types
Case Reports